| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-05-22 14:17:30 UTC |
|---|
| Update Date | 2023-02-21 17:16:01 UTC |
|---|
| HMDB ID | HMDB0001978 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 5-Hydroxypyrazinamide |
|---|
| Description | Pyrazinamide. Pyrazinamide is a drug used to treat tuberculosis in afflicted patients. The drug is largely bacteriostatic, but can be bacteriocidal on actively replicating tuberculosis bacteria. -- Wikipedia; Pyrazinamide is a generic drug and is available in a wide variety of presentations. Pyrazinamide tablets are usually 500mg and form the bulkiest part of the standard tuberculosis treatment regimen. Pyrazinamide tablets are so large that some patients find them impossible to swallow: pyrazinamide syrup is an option for these patients. -- Wikipedia; Pyrazinamide is also available as part of fixed dose combinations with other TB drugs such as isoniazid and rifampicin (Rifater is an example). -- Wikipedia; Pyrazinamide is well absorbed orally. It crosses inflamed meninges and is an essential part of the treatment of tuberculous meningitis. It is metabolised by the liver and the metabolic products are excreted by the kidneys. -- Wikipedia; Pyrazinamide is a pro-drug that stops the growth of Mycobacterium tuberculosis. M. tuberculosis has the enzyme pyrazinamidase which is only active at acidic pH. Pyrazinamidase converts pyrazinamide to the active form, pyrazinoic acid. Pyrazinoic acid inhibits the enzyme fatty acid synthetase I, which is required by the bacterium to synthesise fatty acids. Mutations of the pyrazinamidase gene (pncA) are responsible for pyrazinamide resistance in M. tuberculosis. -- Wikipedia. |
|---|
| Structure | InChI=1S/C5H5N3O2/c6-5(10)3-1-8-4(9)2-7-3/h1-2H,(H2,6,10)(H,8,9) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-carboxamido-5-Hydroxypyrazine | HMDB | | 5-Hydroxy-(8ci)-pyrazinecarboxamide | HMDB | | 5-Hydroxypyrazinecarboxamide | HMDB | | 5-oxo-4,5-Dihydropyrazine-2-carboximidate | Generator, HMDB | | 5-Hydroxypyrazinamide | MeSH |
|
|---|
| Chemical Formula | C5H5N3O2 |
|---|
| Average Molecular Weight | 139.1121 |
|---|
| Monoisotopic Molecular Weight | 139.038176419 |
|---|
| IUPAC Name | 5-oxo-4,5-dihydropyrazine-2-carboxamide |
|---|
| Traditional Name | 5-oxo-4H-pyrazine-2-carboxamide |
|---|
| CAS Registry Number | 13924-96-4 |
|---|
| SMILES | NC(=O)C1=CNC(=O)C=N1 |
|---|
| InChI Identifier | InChI=1S/C5H5N3O2/c6-5(10)3-1-8-4(9)2-7-3/h1-2H,(H2,6,10)(H,8,9) |
|---|
| InChI Key | XENWQEOTDAQROM-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as pyrazinecarboxamides. Pyrazinecarboxamides are compounds containing a pyrazine ring which bears a carboxamide. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazines |
|---|
| Sub Class | Pyrazines |
|---|
| Direct Parent | Pyrazinecarboxamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Pyrazinecarboxamide
- 2-heteroaryl carboxamide
- Heteroaromatic compound
- Vinylogous amide
- Carboxamide group
- Lactam
- Primary carboxylic acid amide
- Carboxylic acid derivative
- Azacycle
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.63 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 8.9944 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.54 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 173.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 659.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 329.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 69.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 210.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 49.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 262.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 289.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 471.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 592.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 87.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 799.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 194.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 220.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 617.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 322.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 262.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 5-Hydroxypyrazinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 1739.4 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 1754.2 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 2619.4 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,1TMS,isomer #2 | C[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 1731.1 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TMS,isomer #2 | C[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 1744.6 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TMS,isomer #2 | C[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 2728.7 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C | 1797.0 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C | 1815.2 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C | 2442.1 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C)C(=O)C=N1 | 1795.5 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C)C(=O)C=N1 | 1892.7 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TMS,isomer #2 | C[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C)C(=O)C=N1 | 2485.3 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C)C(=O)C=N1)[Si](C)(C)C | 1874.2 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C)C(=O)C=N1)[Si](C)(C)C | 1963.0 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,3TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C)C(=O)C=N1)[Si](C)(C)C | 2172.5 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 1966.4 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 1980.1 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=C[NH]C(=O)C=N1 | 2748.0 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 1994.6 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 1936.7 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(C(N)=O)N=CC1=O | 2806.6 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2251.1 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2242.3 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=C[NH]C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2542.1 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1 | 2242.0 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1 | 2276.9 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1 | 2635.7 | Standard polar | 33892256 | | 5-Hydroxypyrazinamide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2523.3 | Semi standard non polar | 33892256 | | 5-Hydroxypyrazinamide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2554.4 | Standard non polar | 33892256 | | 5-Hydroxypyrazinamide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CN([Si](C)(C)C(C)(C)C)C(=O)C=N1)[Si](C)(C)C(C)(C)C | 2444.1 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - 5-Hydroxypyrazinamide EI-B (Non-derivatized) | splash10-004v-9100000000-f3668d75358f611d3aea | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - 5-Hydroxypyrazinamide EI-B (Non-derivatized) | splash10-004v-9100000000-f3668d75358f611d3aea | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5-Hydroxypyrazinamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-059j-9600000000-eed6c6621ac175ebc06f | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 5-Hydroxypyrazinamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 10V, Positive-QTOF | splash10-0006-0900000000-4a9bb4436286b18b224f | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 20V, Positive-QTOF | splash10-00dj-3900000000-aa768b447648d6760f3d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 40V, Positive-QTOF | splash10-0kxr-9000000000-9af022e71bfdc81b06ad | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 10V, Negative-QTOF | splash10-000i-2900000000-b93be6c1c350e992bfab | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 20V, Negative-QTOF | splash10-01pc-5900000000-08d30dda33dea090dd13 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 40V, Negative-QTOF | splash10-0006-9000000000-7932fdb1240ebaf3eef5 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 10V, Positive-QTOF | splash10-006x-0900000000-f65eddb5dd85983512f2 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 20V, Positive-QTOF | splash10-0002-9200000000-97da033a62736d0386e8 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 40V, Positive-QTOF | splash10-00kg-9000000000-493cc79bdf78b0bf3112 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 10V, Negative-QTOF | splash10-000b-9500000000-a9e59e0dfcd47dd21c3d | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 20V, Negative-QTOF | splash10-01pd-9800000000-682ec3f0b7fd06e49819 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 5-Hydroxypyrazinamide 40V, Negative-QTOF | splash10-0006-9000000000-90a8705015cfb3328f31 | 2021-09-22 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
IR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
|---|